Compare Neurocrine Biosciences Inc (NBIX) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Neurocrine Biosciences Inc trades at $155.9 (market cap $15.77B), while ProShares UltraPro Short QQQ ETF trades at $38.91. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | SQQQ | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.50 | $89.43 |
52-Week Low | $123.10 | $36.04 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
SQQQ, a 3x leveraged inverse ETF tracking the Nasdaq-100, trades at $38.31, up 0.34% on the day. Technical indicators are bearish with moving averages signaling sell, while oscillators remain neutral. The ETF is designed for short-term hedging against tech declines but faces structural erosion from daily resets, as highlighted by Seeking Alpha on 2026-06-26. Recent news suggests tactical use amid AI-driven market volatility, but long-term holding risks severe losses.
Outlook: SQQQ offers tactical downside protection in bearish tech markets but is unsuitable for long-term investment due to leverage decay. Risks include rapid value erosion and high volatility, requiring precise timing. Opportunities exist for hedging QQQ exposure during corrections, but investors must monitor Nasdaq-100 trends closely to avoid capital depletion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
